| Literature DB >> 18665831 |
U Panwar1, C Mathews, J O Cullis.
Abstract
Cold haemagglutinin disease (CHAD) is an uncommon condition frequently associated with B-cell lymphoproliferative disorders and is refractory to conventional treatments used in autoimmune haemolytic anaemia. Rituximab has been used in this condition with favourable and lasting responses. Cost has been a major limitation to its use in such indication. We present cost-effectiveness analysis of the use of rituximab in two patients with CHAD. Rituximab successfully controlled haemolysis in both cases of CHAD and was found to be cost-effective through reducing transfusion needs.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18665831 DOI： 10.1111/j.1751-553X.2007.00958.x
Source DB: PubMed Journal: Int J Lab Hematol ISSN： 1751-5521 Impact factor: 2.877